The PARP inhibitor field has been a frustrating one for a while now.
Lynparza, Zejula, Talzenna, Rubraca.
They all work.
They also all hammer the bone marrow because they hit PARP2 along with PARP1, and PARP2 is the one your hematopoietic stem cells need to survive. Anemia, thrombocytopenia, neutropenia. Patients drop doses or drop off treatment entirely.
For years now, the holy grail in this space has been a PARP1-selective inhibitor that keeps the tumor-killing activity without trashing the blood counts.
Acerand Therapeutics just put numbers on the board that suggest they may have one.
The Phase I/II data for ACE-106, presented this week, covered 57 heavily pretreated patients with advanced solid tumors. No dose-limiting toxicities. Lower hematologic tox than the existing PARPs. And in the HRR-mutated cohort, a 32% overall response rate.
That ORR climbs to 50% in metastatic castration-resistant prostate cancer and 67% in ovarian cancer.
ACE-106 ORR by indication (HRR-mutated, n=57)
67%
50%
32%
Source: Acerand Phase I/II update, 57 heavily pretreated patients
For context, AstraZeneca’s Lynparza in PROfound (mCRPC, BRCA-mutated) hit roughly 33% ORR. Clovis’s Rubraca pulled around 45% in similar populations. So 50% in mCRPC isn’t just competitive, it’s pushing the ceiling.
The cleaner safety profile is the real story though. PARP inhibitor adoption has always been capped by tolerability, especially in patients who need to stay on therapy for years. If ACE-106 actually delivers durable responses without the cytopenias, the addressable population gets a lot bigger.
Acerand is now planning a randomized Phase II in prostate cancer, combining ACE-106 with androgen receptor pathway inhibitors. That’s the same playbook AstraZeneca ran with PROpel (Lynparza + Zytiga), which got accelerated approval before label restrictions hit it.
The competitive setup is interesting.
Schrödinger, XinThera, and Repare Therapeutics are all developing PARP1-selective inhibitors. AstraZeneca has its own PARP1-selective candidate (saruparib) in late-stage trials.
So the validation is real, but the field is going to get crowded fast.
What Acerand has right now is a head start with actual response numbers in two solid tumor types where PARPs have struggled to keep market share.
The Phase II readout is going to matter… a lot.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
One more thing worth flagging: the company is calling this a Phase I/II study, but they’re already updating it to a Phase III timeline in their press release headline. That’s either a signal of confidence or a signal of regulatory ambition. Either way, it suggests they think the data are strong enough to bypass the usual mid-stage scrum.
The real test will be durability of response and how the safety profile holds up over longer dosing. PARP toxicity tends to creep in with chronic exposure. If Acerand can avoid that with a true PARP1-selective mechanism, they have a real shot at displacing the incumbents.
Watch for the Phase II prostate readout. That’s where this story either becomes a category killer or fades into the pack.
